Regeneron Pharmaceuticals, Inc. $REGN Position Boosted by Mediolanum International Funds Ltd

Mediolanum International Funds Ltd lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 56.4% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 71,209 shares of the biopharmaceutical company’s stock after purchasing an additional 25,674 shares during the period. Mediolanum International Funds Ltd’s holdings in Regeneron Pharmaceuticals were worth $53,356,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. WPG Advisers LLC lifted its stake in Regeneron Pharmaceuticals by 312.5% during the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 25 shares during the last quarter. SHP Wealth Management acquired a new position in Regeneron Pharmaceuticals in the fourth quarter worth approximately $26,000. Titan Wealth CI Ltd acquired a new position in Regeneron Pharmaceuticals in the fourth quarter worth approximately $29,000. Board of the Pension Protection Fund bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $31,000. Finally, Kemnay Advisory Services Inc. bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $31,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Trading Down 0.3%

Regeneron Pharmaceuticals stock opened at $676.69 on Friday. The company has a 50 day moving average price of $640.99 and a 200 day moving average price of $718.41. Regeneron Pharmaceuticals, Inc. has a 52 week low of $541.00 and a 52 week high of $821.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57. The firm has a market capitalization of $71.54 billion, a price-to-earnings ratio of 16.49, a P/E/G ratio of 1.50 and a beta of 0.24.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The firm had revenue of $3.61 billion for the quarter, compared to analysts’ expectations of $3.48 billion. During the same period in the previous year, the company posted $8.22 EPS. The company’s quarterly revenue was up 19.0% compared to the same quarter last year. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.12 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were given a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.16%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the transaction, the director owned 17,303 shares in the company, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Negative Sentiment: Multiple law firms announced or promoted securities class-action activity tied to REGN, including a newly filed class action and related investor deadline notices. These developments can weigh on sentiment because they highlight alleged disclosure issues and raise the risk of legal costs or settlement uncertainty. Article: Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. (REGN)
• Negative Sentiment: Additional reminders from Faruqi & Faruqi, Robbins LLP, Levi & Korsinsky, and Bragar Eagel & Squire kept the lawsuit story in focus, reinforcing legal overhang for shareholders. Article: REGN Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Filed Against Regeneron Pharmaceuticals, Inc.
• Neutral Sentiment: A market commentary piece said Regeneron has rebounded and may still look undervalued, but also questioned whether the upside is already reflected in the shares, making the stock’s near-term direction less clear. Article: Regeneron Pharmaceuticals (REGN) Rebounds As Undervalued View Holds, Is The Upside Already Priced In?
• Neutral Sentiment: Brokerage coverage cited by American Banking News said REGN carries a “Moderate Buy” consensus, which supports the long-term outlook but is less likely to move the stock immediately than the litigation headlines. Article: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of “Moderate Buy” by Brokerages

Analyst Upgrades and Downgrades

REGN has been the subject of a number of recent research reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 24th. Wall Street Zen cut Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. Benchmark raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 target price on the stock in a research report on Tuesday, July 7th. Royal Bank Of Canada reduced their target price on Regeneron Pharmaceuticals from $707.00 to $696.00 and set a “sector perform” rating for the company in a report on Tuesday, July 7th. Finally, BMO Capital Markets decreased their price target on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a research report on Monday, May 18th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $787.67.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.